Split dosing cuts GI side effects vs once-weekly — here’s the math. Covers 0.25-0.5mg 3x/week, titration, and reconstitution.
Tirzepatide is a dual GLP-1/GIP receptor agonist that represents the next generation of incretin-based therapies. By targeting both GLP-1 and GIP receptors, it provides superior weight loss and glycemic control compared to single-target GLP-1 agonists like semaglutide.
FDA-approved as FDA-approved for diabetes and weight management with clinical data showing up to 22.5% weight loss in the SURMOUNT trials.
Research peptide protocols use a 3x weekly approach with lower total doses than pharmaceutical formulations:
Start at 0.25 mg 3x weekly for 2-4 weeks to assess tolerance, then increase to 0.5 mg 3x weekly. The split dosing provides more stable levels than once-weekly injection.
For the full tirzepatide peptide profile, vendor pricing, and stack protocols, see our Tirzepatide peptide page.
Loading (Weeks 1-4): Start at 0.25 mg three times per week (0.75mg total weekly) to assess tolerance. The dual GLP-1/GIP mechanism can cause more intense initial side effects than single-target agonists.
best injection sites to avoid pip (post injection pain)
my experience with 500mg test vs 300mg test results
is it worth running an oral”only cycle for your first time
Latest Post: Nandrolone Phenylpropionate vs Decanoate (DECA) Benefits Our newest member: Josh Sutton Recent Posts Unread Posts
